Noha Shawky Elsayed

Dr. Noha Shawky Elsayed


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EDEvangeline Deer
Evangeline Deer
BLBabbette LaMarca LaMarca
Babbette LaMarca LaMarca
JRJane Reckelhoff
Jane Reckelhoff
NENoha Shawky Elsayed
Noha Shawky Elsayed
KEKristin of Mississippi Medical Edwards
Kristin of Mississippi Medical Edwards
Despite decades of research, the pathophysiology of preeclampsia (PE) and polycystic ovary syndrome (PCOS) remains poorly understood. Notably, no new FDA-approved treatments for PE have emerged in over 50 years. PCOS, a common endocrine disorder, increases a woman’s risk of developing PE. Both conditions share overlapping mechanisms, including insulin resistance, chronic inflammation, endothelial dysfunction, and oxidative stress. While physiological levels of reactive oxygen species (ROS) are essential for reproduction, excess ROS contributes to cellular and mitochondrial damage. This review will assess current evidence linking oxidative stress and mitochondrial dysfunction to the development of PCOS and PE, explore their shared mechanisms, and evaluate emerging therapeutic interventions. Ultimately, a comprehensive understanding of these shared mechanisms may inform strategies for early prediction, prevention, and the treatment of PE and PCOS.

30 November 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
NENoha Shawky Elsayed
Noha Shawky Elsayed
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women at reproductive age. PCOS diagnosis (Rotterdam criteria) is based on the presence of two out of three criteria; clinical and/or biochemical hyperandrogenism, oligo- or an-ovulation and polycystic ovaries. PCOS women suffer from a constellation of reproductive and metabolic abnormalities including obesity and insulin resistance. PCOS women also have increased blood pressure and increased risk of cardiovascular diseases (CVD). In-utero, offspring of PCOS women are exposed to altered maternal hormonal environment and maternal obesity (for most of PCOS women). Offspring of PCOS women could also be subject to genetic susceptibility, the transgenerational transmission of some of the PCOS traits or epigenetic changes. Offspring of PCOS women are commonly reported to have an abnormal birth weight, which is also a risk factor for developing CVD and hypertension later in life. Although studies have focused on the growth pattern, reproductive and metabolic health of children of PCOS women, very limited number of studies have addressed the risk of hypertension and CVD in those offspring particularly as they age. The current narrative review is designed to summarize the available literature (both human studies and experimental animal studies) and highlight the gaps in addressing hypertension and CVD risks in offspring of PCOS women or hyperandrogenemic female animal models.

3 January 2022 in Journal Of Hypertension
Verified
Journal Article
Closed access
NENoha Shawky Elsayed
Noha Shawky Elsayed
CDCarolina Dalmasso
Carolina Dalmasso
NONorma B. Ojeda
Norma B. Ojeda
YZYvonne Zuchowski
Yvonne Zuchowski
NSNina Stachenfeld
Nina Stachenfeld
JRJane F. Reckelhoff
Jane F. Reckelhoff
Background: Polycystic ovary syndrome (PCOS) is characterized by reproductive and metabolic dysfunction, and elevated blood pressure (BP). The cardiometabolic consequences of maternal hyperandrogenemia on offspring, either as adults or with aging, have not been well studied. We previously found that male offspring of hyperandrogenemic female (HAF) rats, a model of PCOS, are normotensive but have an exaggerated pressor response to angiotensin (Ang) II. Method: In this study, the hypothesis was tested that adult and aging female offspring of HAF rats develop a metabolic and hypertensive phenotype. Control and HAF rats were implanted prepubertally with placebo or dihydrotestosterone pellets, which continued throughout pregnancy and lactation. Results: Female offspring of HAF dams had lower birth weight than female control offspring. Although female HAF offspring (aged 16–24 weeks) had no differences in intrarenal Ang II, plasma lipids or proteinuria, they did have lower intrarenal Ang (1–7) and lower nitrate/nitrite excretion than controls. Adult HAF offspring had similar baseline BP as controls, but had an attenuated pressor response to Ang II. With aging (16–20 months), female HAF offspring remained normotensive with an attenuated pressor response to Ang II and high salt diet but more proteinuria and higher intrarenal Ang(1–7) than controls. Conclusion: Taken together, these data suggest that female HAF offspring are protected from developing hypertension, but may be at risk for renal injury with aging. Future studies are necessary to determine whether adult and postmenopausal offspring of PCOS women are at increased risk for cardiovascular dysfunction. Graphical abstract: http://links.lww.com/HJH/B820

21 July 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
PKPrerna Kumar
Prerna Kumar
EDEvangeline Deer
Evangeline Deer
NENoha Shawky Elsayed
Noha Shawky Elsayed
Sex steroids are known to regulate endothelial function, vascular tone, inflammatory signaling, oxidative stress, and extracellular matrix remodeling, all of which contribute to cardiovascular (CV) risk [1]. They also modulate blood pressure (BP), fluid balance, lipid metabolism, and inflammation, contributing to sex-based differences in health and disease. Despite growing recognition of these influences, key molecular mechanisms and clinical implications remain poorly understood. This research topic was designed to help better understand the molecular, physiological, and clinical effects of sex hormone signaling on CV and renal health in both sexes across different periods of life.In women, critical periods of life that are coupled with hormonal changes can shape their future risks of CV disease (CVD) [2]. Women are generally accepted to be at lower risk of CVD compared to men during reproductive years of their lives. However, unique sexspecific reproductive and pregnancy history in women that occur in those years can shape their future risks [3]. Moreover, during the menopausal transition, women demonstrate characteristic shifts in sex hormone profiles accompanied by adverse alterations in body composition, lipid levels, and vascular function, collectively contributing to an elevated risk of postmenopausal CVD [4]. This highlights the critical need to focus more studies on women undergoing menopausal transition and its correlation to the heightened CVD risk.In this context, the study by Wang et al investigated differences in multiple clinical parameters between perimenopausal women (n = 176) with CVD and postmenopausal women (n = 120) with CVD across different age groups (40-44, 45-49, 50-54). The authors reported that postmenopausal women had significantly higher body mass index (BMI), waist-to-hip ratio, total body fat percentage and distribution, systolic and diastolic BP with no change in lipid profile and oral glucose tolerance compared with perimenopausal women [DOI 10.3389/fendo.2025.1681941]. Peri-and post-menopause are periods where women are at an increased risk of developing metabolic disorders, such as insulin resistance (IR), abdominal obesity and elevated blood sugar, which also increases the incidence of CVD [5]. The estimated glucose disposal rate (eGDR) is recognized as a reliable marker of IR that is independently associated with an increased risk of CVD, coronary heart disease (CHD), and stroke. The meta-analysis performed by Zhang et. al. provides robust evidence regarding eGDR's prognostic utility and its continuous relationship with CVD risk [DOI 10.3389/fendo.2025.1740472]. In this metaanalysis, electronic databases such as PubMed, Web of Science and Embase were searched for cohort studies reporting eGDR and CVD risk. The included studies enrolled adult subjects (56 to 63 years; both sexes) without baseline CVD, measured eGDR at baseline and reported hazard ratio, with follow-up durations ranging from 5.6 to 14.1 years. The study reported that higher baseline eGDR levels are associated with a reduced risk of CVD, stroke, and CHD in individuals without preexisting CVD. Subgroup analyses indicated that variables such as sex, sample size, follow-up duration, and prediabetes/diabetes status did not significantly influence the observed associations. Furthermore, dose-response analysis demonstrated a linear inverse relationship between eGDR and CVD risk. Whether changes in eGDR can be utilized as a prognostic marker for CVD in women during menopausal transition is an area that needs further investigation.The study by Wang and colleagues was directed towards investigating potential biomarkers that could be used as prognostic tools for left atrial reverse remodeling (LARR) in patients (~65 years; both sexes) with atrial fibrillation (AF) after catheter ablation (CA) [DOI 10.3389/fendo.2025.1717422]. CA for AF is an important rhythmcontrol strategy in symptomatic patients with paroxysmal or persistent AF who are refractory or intolerant to antiarrhythmic drugs. Corin is a type II transmembrane serine protease highly expressed in cardiomyocytes and converts pro-atrial natriuretic peptide (ANP)/pro-brain natriuretic peptide (BNP) into mature ANP/BNP, and is associated with CVD [6,7]. In the total cohort, the plasma corin concentrations drawn pre-and postprocedure in the LARR group were significantly higher than those in the non-LARR group.However, sex-specific subgroup analysis, male patients with LARR had significantly higher pre-CA plasma corin concentrations than in those without LARR, whereas no differences were observed in post-CA or among female patients, highlighting the importance of the development of sexspecific CVD markers. Importantly, while plenty of studies examined the role of estrogen and testosterone in CV and renal physiology, the contribution of progesterone signaling to cardiorenal physiology/pathophysiology in females and males remains unclear. Nguyen and Kriegel summarized evidence on the role of progesterone, beyond reproduction, highlighting its importance in cardiorenal health and disease [DOI 10.3389/fendo.2026.1837458]. On the vasculature, progesterone lowers vascular resistance through two mechanisms: increased endothelial nitric oxide production and direct effects on smooth muscle, however its effects on BP remain unclear [8,9]. Additionally, progesterone lacks protective effects in atherosclerotic models when supplied during the development of associated pathology. The authors also summarized the renal effects of progesterone replacement in ovariectomized animal models of kidney disease including its effects on water reabsorption, ion transport, autonomic function, and renal vasculature in order to isolate the progesterone-specific effects on the kidney. Progesterone receptors are expressed in many male tissues. Experimental studies indicate that progesterone has limited effects on renal tubular transporters; sodium glucose transporter1...